18 May 2013
Keywords: all, ctcl, patients, see, response, zolinza, jco
Article | 30 July 2007
US drug major Merck & Co says that a trial of Zolinza (vorinostat) in patients with advanced, refractory cutaneous T-cell lymphoma ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 July 2007
17 May 2013
© 2013 thepharmaletter.com